Need help finding what you are looking for?
Contact Us
PUBLISHER: FirstWord Group | PRODUCT CODE: 1355800
PUBLISHER: FirstWord Group | PRODUCT CODE: 1355800
Bladder Cancer - KOL Insight
PUBLISHED:
PAGES:
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
While Merck & Co Keytruda + Astellas/Seagen's Padcev forges ahead, how do KOLs see the prospects of Keytruda + Taiho Pharmaceutical's futibatinib combination? How do experts assess FKD Therapies/Ferring Pharmaceuticals much needed Adstiladrin? Could a combination therapy strategy reinvigorate AstraZeneca's Imfinzi? KOLs critically assess the prospects of launched and pipeline therapies.
In addition to the full report, licensed users have access to the Report Highlights slidedeck and the following KOL Bulletins via the Attachments area.
- 03 Oct 23 KOL Bulletin -- Views on the results of Phase III EV-302 trial of Keytruda and Padcev in bladder cancer
Table of Contents
Executive summary (3)
Treatment algorithm
Research objectives (5)
Immunotherapies (69)
- Marketed therapies (42)
- Keytruda (pembrolizumab; Merck & Co.) (13)
- Opdivo (nivolumab; Bristol Myers Squibb) (14)
- Tecentriq (atezolizumab; Roche) (6)
- Bavencio (avelumab; Merck Group/Pfizer) (9)
- Pipeline therapies (27)
- Imfinzi (durvalumab; AstraZeneca) (11)
- Sasanlimab (Pfizer) (8)
- Cetrelimab (Janssen) (8)
Antibody-drug conjugates (21)
- Marketed therapies (21)
- Padcev (enfortumab vedotin; Astellas/Seagen) (9)
- Trodelvy (sacituzumab govitecan; Gilead) (12)
Fibroblast growth factor receptor (FGFR) inhibitors (9)
- Marketed therapies (9)
- Balversa (erdafitinib; Janssen) (9)
Tyrosine kinase inhibitors (7)
- Pipeline therapies (7)
- Cabometyx (cabozantinib; Exelixis/Ipsen) (7)
Other modes of action (34)
- Marketed therapies (11)
- Adstiladrin (nadofaragene firadenovec; FKD Therapies/Ferring Pharmaceuticals) (11)
- Pipeline therapies (23)
- Anktiva (N-803; ImmunityBio) (10)
- CG0070 (cretostimogene grenadenorepvec; CG Oncology) (6)
- Ruvidar (TLD-1433; Theralase) (7)
Future treatment paradigm (7)
- Key insights summary (7)
- Biomarkers for better patient selection remain an important unmet need in bladder cancer (5)
Appendix (3)
- KOL details (3)
- KOLs from North America (1)
- KOLs from Europe (1)
KOL Bulletins (2)
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.